Cryoprecipitated-Antihemophilic Factor
PreclinicalBiologic
Cryoprecipitated-Antihemophilic Factor is one of 41 biologic programs targeting Hemorrhage. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
137 competitors in Hemorrhage
#DrugCompanyPhaseTrials
1Cytotec
PfizerPhase 3
Cyklokapron
AAmring
Phase 3
Activase
RochePhase 3
Glypressin
MMallinckrodt
Phase 3
Tylenol
KKenvue Brands
Phase 3
Indocin
LLife Extension Foundation Inc.
Phase 3
Virazole
CConrado Roberto Hoffmann Filho
Phase 3
Betadine
BBecton, Dickinson and Company
Phase 3
Zocor
OOrganon and Co
Phase 3
Statins
SanofiPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- CCerus Corporation